Literature DB >> 30702513

In-vitro viral suppressive capacity correlates with immune checkpoint marker expression on peripheral CD8+ T cells in treated HIV-positive patients.

Pieter Pannus1,2,3, Philipp Adams1,2,4, Elisabeth Willems1, Leo Heyndrickx1, Eric Florence1, Sofie Rutsaert3, Ward De Spiegelaere5, Linos Vandekerckhove3, Carole Seguin-Devaux4, Guido Vanham1,2.   

Abstract

OBJECTIVE: To determine whether viral suppressive capacity (VSC) of CD8+ T cells can be boosted by stimulation with HIV-1 peptides and whether the ability to control HIV-1 replication correlates with immunological (cytokine production and CD8+ T-cell phenotype) and viral reservoir measures (total HIV-1 DNA and cell-associated RNA) in well treated HIV-infected chronic progressors.
DESIGN: We compared VSC of peripheral CD8+ T cells to cytokine production profile in response to peptide stimulation, detailed phenotype (17-color flow-cytometry), reservoir size (total HIV-1 DNA), basal viral transcription (unspliced cell-associated RNA) and inducible viral transcription (tat/rev induced limiting dilution assay) in 36 HIV+ patients on cART and six healthy donors.
RESULTS: We found that the VSC of CD8+ T cells can be increased by prior stimulation with a pool of consensus HIV-1 gag peptides in a significant proportion of progressor patients. We also found that VSC after peptide stimulation was correlated with higher expression of immune checkpoint markers on subsets of terminally differentiated effector memory (TEMRA) CD8 T cells as well as with production of IFN-γ, TNF-α and IL-10. We did not find a correlation between VSC and viral reservoir measures.
CONCLUSION: These results add to a small body of evidence that the capacity of CD8+ T cells to suppress viral replication is increased after stimulation with HIV-1 peptides. Interestingly, this VSC was correlated with expression of immune checkpoint markers, which are generally considered to be markers of exhaustion. Our findings may guide further investigations into immune phenotypes correlated with viral suppression.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30702513     DOI: 10.1097/QAD.0000000000002068

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  3 in total

1.  Cytotoxic CD8+ T Cells Expressing CXCR5 Are Detectable in HIV-1 Elite Controllers After Prolonged In Vitro Peptide Stimulation.

Authors:  Philipp Adams; Gilles Iserentant; Jean-Yves Servais; Linos Vandekerckhove; Guido Vanham; Carole Seguin-Devaux
Journal:  Front Immunol       Date:  2021-02-24       Impact factor: 7.561

2.  Therapeutic Vaccine in Chronically HIV-1-Infected Patients: A Randomized, Double-Blind, Placebo-Controlled Phase IIa Trial with HTI-TriMix.

Authors:  Wesley de Jong; Lorna Leal; Jozefien Buyze; Pieter Pannus; Alberto Guardo; Maria Salgado; Beatriz Mothe; Jose Molto; Sara Moron-Lopez; Cristina Gálvez; Eric Florence; Guido Vanham; Eric van Gorp; Christian Brander; Sabine Allard; Kris Thielemans; Javier Martinez-Picado; Montserrat Plana; Felipe García; Rob A Gruters
Journal:  Vaccines (Basel)       Date:  2019-12-06

3.  The CD38/NAD/SIRTUIN1/EZH2 Axis Mitigates Cytotoxic CD8 T Cell Function and Identifies Patients with SLE Prone to Infections.

Authors:  Eri Katsuyama; Abel Suarez-Fueyo; Sean J Bradley; Masayuki Mizui; Ana V Marin; Lama Mulki; Suzanne Krishfield; Fabio Malavasi; Joon Yoon; Shannan J Ho Sui; Vasileios C Kyttaris; George C Tsokos
Journal:  Cell Rep       Date:  2020-01-07       Impact factor: 9.423

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.